Pacer Advisors Inc. Increases Stake in Boston Scientific Co. (NYSE:BSX)

Pacer Advisors Inc. lifted its position in Boston Scientific Co. (NYSE:BSX) by 21.8% in the 4th quarter, HoldingsChannel.com reports. The firm owned 138,057 shares of the medical equipment provider’s stock after acquiring an additional 24,754 shares during the quarter. Pacer Advisors Inc.’s holdings in Boston Scientific were worth $12,331,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also modified their holdings of the company. Susquehanna Fundamental Investments LLC acquired a new stake in shares of Boston Scientific in the second quarter worth approximately $2,273,000. Ascent Group LLC lifted its position in Boston Scientific by 11.8% during the second quarter. Ascent Group LLC now owns 7,480 shares of the medical equipment provider’s stock worth $576,000 after buying an additional 790 shares in the last quarter. Creative Planning lifted its position in Boston Scientific by 13.7% during the second quarter. Creative Planning now owns 189,545 shares of the medical equipment provider’s stock worth $14,597,000 after buying an additional 22,901 shares in the last quarter. NewEdge Advisors LLC grew its holdings in Boston Scientific by 34.0% in the 2nd quarter. NewEdge Advisors LLC now owns 81,307 shares of the medical equipment provider’s stock valued at $6,261,000 after buying an additional 20,644 shares in the last quarter. Finally, Sunbelt Securities Inc. boosted its position in shares of Boston Scientific by 85.8% during the 2nd quarter. Sunbelt Securities Inc. now owns 1,213 shares of the medical equipment provider’s stock valued at $93,000 after acquiring an additional 560 shares during the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific Stock Performance

Shares of BSX stock opened at $102.41 on Wednesday. The stock has a fifty day moving average price of $92.50 and a 200 day moving average price of $85.63. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.02 and a current ratio of 1.48. The stock has a market cap of $150.93 billion, a PE ratio of 84.63, a P/E/G ratio of 2.63 and a beta of 0.80. Boston Scientific Co. has a 1 year low of $60.78 and a 1 year high of $102.93.

Analyst Ratings Changes

A number of research analysts recently commented on BSX shares. BTIG Research upped their price objective on Boston Scientific from $84.00 to $93.00 and gave the company a “buy” rating in a report on Monday, October 14th. Wells Fargo & Company lifted their price objective on shares of Boston Scientific from $98.00 to $100.00 and gave the company an “overweight” rating in a report on Wednesday, December 11th. Morgan Stanley boosted their price objective on Boston Scientific from $92.00 to $100.00 and gave the stock an “overweight” rating in a research report on Thursday, October 24th. JPMorgan Chase & Co. raised their price target on Boston Scientific from $100.00 to $110.00 and gave the company an “overweight” rating in a research note on Monday, December 16th. Finally, TD Cowen boosted their target price on Boston Scientific from $100.00 to $110.00 and gave the stock a “buy” rating in a research note on Thursday, December 12th. Three equities research analysts have rated the stock with a hold rating, twenty have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $97.26.

Insider Transactions at Boston Scientific

In other news, EVP John Bradley Sorenson sold 4,119 shares of the firm’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $90.02, for a total transaction of $370,792.38. Following the completion of the transaction, the executive vice president now directly owns 35,319 shares of the company’s stock, valued at $3,179,416.38. This trade represents a 10.44 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Arthur C. Butcher sold 14,010 shares of the stock in a transaction on Monday, November 25th. The shares were sold at an average price of $89.27, for a total value of $1,250,672.70. Following the sale, the executive vice president now owns 978 shares in the company, valued at approximately $87,306.06. This trade represents a 93.47 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 29,989 shares of company stock valued at $2,702,261 in the last 90 days. 0.50% of the stock is currently owned by insiders.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.